A practical reference on nitric oxide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-28 and is reviewed periodically as new material appears.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
In drug manufacture, validation is a documented process to ensure a product meets its required specifications and quality. The process of establishing documentary evidence demonstrating that a procedure, process, or activity carried out in testing and then production maintains the desired level of compliance at all stages. In the pharmaceutical industry, it is very important that in addition to final testing and compliance of products, it is also assured that the process will consistently produce the expected results. The desired results are established in terms of specifications for outcome of the process. Qualification of systems and equipment is therefore a part of the process of validation. Validation is a requirement of food, drug and pharmaceutical regulating agencies such as the US FDA and their good manufacturing practices guidelines. Since a wide variety of procedures, processes, and activities need to be validated, the field of validation is divided into a number of subsections including the following:
Reddy's international marketing successes were built on a strong manufacturing base which itself was a result of inorganic growth through acquisition of international and national facilities. Reddy's merged Cheminor Drug Limited (CDL) with the primary aim of supplying active pharmaceutical ingredients to the technically demanding markets of North America and Europe. This merger also gave Reddy's an entry into the value-added generics business in the regulated markets of APIs.
The oil is distilled from the wood of the entire tree including stump and roots. Australian sandalwood (S. spicatum) is unique in that the white sapwood does not require removal before distilling the oil, while Indian Sandalwood (S. album) does require removal of the sapwood prior to distillation.
== Education and career == Brenner graduated from Wesleyan University with a bachelor's degree in biology in 1983. After working for the biotechnology companies Chiron Corporation and DNAX Research Institute, Brenner attended graduate school at Stanford University School of Medicine. At Stanford he worked with Robert S. Fuller, receiving his Ph.D. in Cancer Biology in 1993. Brenner conducted post-doctoral research at Brandeis University with Gregory Petsko and Dagmar Ringe. Brenner then joined the faculty at Thomas Jefferson University, where he worked from 1996 to 2003, becoming Director of the Structural Biology & Bioinformatics Program in 2000. He moved to Dartmouth Medical School in 2003, serving as associate director for Basic Sciences at Norris Cotton Cancer Center (now named Dartmouth Cancer Center) from 2003 to 2009. In 2009 he joined the University of Iowa (UI) as Professor and Head of Biochemistry. In 2010 he was awarded the Roy J. Carver Chair of Biochemistry at UI, holding that position until 2020. In 2020, Brenner joined City of Hope National Medical Center in Duarte, California as the inaugural chair of a new department of diabetes and cancer metabolism created to focus at the intersection of metabolic disturbances with diseases such as cancer and diabetes.
== Methods == Several methods for cell lysis exist, sometimes used in combination. Examples include liquid homogenization, freeze thawing, and physical disruption such as sonication, or the use of hypotonic solutions that cause osmotic swelling and eventual bursting of the cell.
Sources: en.wikipedia.org
== Target == DkTx is a specific TRPV1 receptor agonist and acts as a bivalent ligand, which gives it high affinity to its target. The TRPV1 channel is a member of the group of TRP ion channels, which are all known to be responsible for sensory signaling, such as mechanosensation, thermoception, and nociception. TRPV1 itself is a nonselective cation channel located in the plasma membrane of nociceptive dorsal root ganglions. It can be activated in several ways, such as by noxious heat, capsaicin, extracellular proteins, and other inflammatory agents. However, binding locations can differ, e.g., capsaicin does not bind to the outer pore region but to the S3-S4 region of the channel. The potency of this toxin binding to the TRPV1 channel, as quantified with the half maximal effective concentration (EC50) of DkTx is 0.23 μM. Owing to its bivalent structure, this potency is much higher compared to single K1 and K2 motifs or other vanillotoxins binding to the TRPV1 channel. Vanillotoxins (VaTx, or Vanilloids) are toxins that are TRPV1 agonists that target the channel on its outer pore region. For this reason, DkTx is considered a vanillotoxin. Different from the reversible interaction of the other three VaTx toxins (VaTx1, VaTx2 and VaTx3), binding of DkTx is irreversible and inflicts persistent TRPV1 channel activity.
On 3 January 2026, the United States launched a military strike in Venezuela and captured incumbent Venezuelan president Nicolás Maduro and his wife, Cilia Flores. The US operation, codenamed Operation Absolute Resolve, began around 2 a.m. local time, when explosions were observed. The US Armed Forces bombed infrastructure across northern Venezuela to suppress air defenses as an apprehension force attacked Maduro's compound in Caracas. Approximately 80 people, including Venezuelan and Cuban military and civilians, died and seven American soldiers were wounded. Maduro and Flores were transported to New York City by US forces and were indicted on drug trafficking charges to which Maduro and Flores pleaded not guilty. US president Donald Trump and his administration justified the operation as a law-enforcement action with military support, saying that the president has "inherent constitutional authority" to undertake such an act. Venezuelan vice president Delcy Rodríguez denounced Maduro's "kidnapping". Venezuelan officials said at least 23 Venezuelan security officers were killed during the attack. The Cuban government said that 32 members of the Cuban military and intelligence agencies were killed. Officials in the United Nations (UN), the US, and other countries, as well as international law experts said the raid violated the UN Charter and Venezuela's sovereignty. Other reactions around the world included celebrations by the Venezuelan diaspora and protests against the attack.
Creation-science means origin through abrupt appearance in complex form, and includes biological creation, biochemical creation (or chemical creation), and cosmic creation. (...) Creation-science does not include as essential parts the concepts of catastrophism, a world-wide flood, a recent inception of the earth or life, from nothingness (ex nihilo), the concept of kinds, or any concepts from Genesis or other religious texts.
The precise extent to which KOR agonism underlies ibogaine's anti-addictive properties is unclear. In animal models, ibogaine administration has been shown to reduce self-administration of opioids, stimulants, and alcohol, ameliorate withdrawal symptoms, and decrease drug-seeking behavior. A 2022 systematic review of 24 studies involving 705 participants found that both ibogaine and noribogaine show promise in treating substance use disorders and comorbid depressive symptoms.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.